Buzulfan review

Buzulfan, a common cancer medicament, is known to slow down the neoplastic activity of malignant cells. More specifically, it is a generic and non-specific cell type alkylating antineoplastic agent that was initially created as a therapeutic medicament for chronic myeloid leukemia and has been reclassified as a generic medicament for cancer cells.

This medicament is supposed to control the burden of tumor formation and significantly slow down metastasis of cancer cells to other regions in the body. It is not able to fully impede the progress of the cancer cells, as it is incapable of reversing the overall cellular aberration effects of the cancer cells. Cytogenic abnormalities still continue to progress, but at a much slower rate than without the medicament.

Buzulfan is given to cancer patients that are susceptible to chemotherapy and medicament induction therapy. The medicament works on a cellular level by producing Guanine-guanine strands of genetic output as the medicament attacks the carbon strand in the mesylate group in a malignant cancer cell. This occurs in large success rates for the target cancer cell and results in an apoptotic state. The result may also decrease overall strength as massive cellular destruction on the target area is occurring as evidenced by destruction of normal cells, especially in bone marrows.

Buzulfan is an alternative option for non-operative stem cell transplantation, therefore increasing receptivity for an oncoming transplant of stem cells.

Cancer patients should have proper information regarding the effects of the medicament and the proper supervision and expertise of a qualified doctor.

Buzulfan is a palliative medicament in doses of 60 micrograms per body weight in kilos, with a maximum of 4 milligrams per day. For treatment of Polycythemia vera, 4 to 6 milligrams is recommended per day over 4 to 6 weeks. For thrombocythaemia, 2 to 4 milligrams per day is recommended. Conditioning therapeutic medicament plans require about 3.5 to 4 milligram per body weight in kilos per day, given in four doses, totaling 14 to 16 milligrams per kilo body weight.

Side effects for Buzulfan may include general toxicity leading to fibrosis in the pulmonary tract, seizures, wasting of the muscles and organs, and cases of liver malfunction and failure. As for seizures, phenytoin medicament may be used to lessen the occurrence.

Let your doctor know the medicaments already being used to determine possible medicament-to-medicament interactions. Special consideration needs to be given to antifungal medicaments such as azole variants. This medicament also is contraindicated with acetaminophens, phenothiazines and other cancer medicaments such as cyclosporine.

If contraindications of medicaments is suspected or determined, take medicament and cautiously use the product three days after last previous medicament is used.

Acetaminophen is not to be used alongside Buzulfan since it raises blood levels and may increase the risk of complicated high blood pressure.

Buzulfan has the following structural formula:

Chemical structure of buzulfan

• Molecular formula of buzulfan is C6H14O6S2
• Chemical IUPAC Name is 1,4-bis(methylsulfonyloxy)butane
• Molecular weight is 246.304 g/mol

Generic name: Busulfan

Brand name(s): Busulfex, Busulphan, Busulphane, Citosulfan, Leucosulfan, Mablin, Mielevcin, Mielosan, Mielucin, Milecitan, Mileran, Misulban, Mitosan, Mitostan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Sulphabutin

  Your Buzulfan review